Furthermore, EGFR tyrosine kinase inhibitor (TKI) therapy could disrupt Beclin 1 tyrosine phosphorylation and restores autophagy in non‐small‐cell lung carcinoma (NSCLC) cells.60 Here, EGFR is linked to non-small cell lung carcinoma.